Alnylam Pharmaceuticals, Inc.
ALNYLast close · Oct 16, 2026231.83−2.20 (−0.94%)
Market cap$31.0B
Of the 85 managers this site tracks, 2 held Alnylam Pharmaceuticals (ALNY) at the end of Q2 2026, their latest 13Fs. The largest position by value was Dodge & Cox's, $588.6M; Bridgewater's ($30.0M) follows. No Schedule 13D or 13G is on file for ALNY from the activists and large holders the site follows.
Superinvestors holding ALNY
| Manager | Firm | Quarter | Shares | Value |
|---|---|---|---|---|
| Dodge & Cox | Dodge & Cox | Q2 2026 | 2M | $588.6M |
| Bridgewater | Bridgewater Associates, LP | Q2 2026 | 99,584 | $30.0M |
13D/13G are SEC beneficial-ownership disclosures, triggered only above 5%; a 13F is a quarterly snapshot filed up to 45 days after quarter end. Superinvestor names link to their full portfolios under Investors.